Tacrolimus for Skin

Besides An Essential Skin Care Ingredient, Tacrolimus Can Do More!

• 2024-01-30
  

  Revolutionary Breakthrough: Hengrui Pharmaceuticals' Immunosuppressant Tacrolimus Sustained-Release Capsule Approved for US Market

  In a groundbreaking development, Hengrui Pharmaceuticals has achieved a major milestone with the approval of their immunosuppressant drug, Tacrolimus sustained-release capsule, for the US market. This remarkable achievement marks the first-ever generic version of the drug to be approved by the US Food and Drug Administration (FDA), as well as the first generic product of its kind in China. With this approval, Hengrui Pharmaceuticals is set to make a significant impact on the US market and expand their global reach.
• 2024-10-12
  

  Contradictions Between FDA and Hengrui Pharmaceuticals: Behind the Launch of a New Paclitaxel Drug, a Sales Puzzle of 4.3 Billion RMB

  Tacrolimus sustained-release capsule is an important drug to prevent graft rejection after adult kidney transplantation. Its sustained-release capsule dosage form was approved by the US FDA and recognized as the first imitation drug of this variety, and it is also the first imitation product in China. The product was approved for sale in China in June 2022.
• 2024-08-19
  

  Hengrui Pharmaceuticals Shocks the World! First Bupivacaine Liposome Injection Obtains FDA Approval, Enjoying a 6-Month Monopoly in the US Market, Expected Revenue of Over 4 Billion Yuan!

  Looking back at history, buprenorphine liposome injection is not the first high-end generic drug launched by Hengrui Pharmaceuticals. The company has accumulated rich experience in the development of high-end formulations. According to PharmZoom data, in January 2022, ondansetron oral disintegrating film (oral disintegrating film formulation) was approved for marketing in China. Tacrolimus sustained-release capsules (sustained-release formulation) were approved for marketing in China in June 2022 and approved by the US FDA in January 2024, becoming a dual-first-in-class high-end formulation generic drug. The launch of bupivacaine liposome injection in the US marks another important step forward in Hengrui Pharmaceutical's international development of high-end formulations.
• 2024-04-03
  

  Breakthroughs in the $5 Billion Vitiligo Market: A New Era Dawns

  The approval of only one biotherapeutic, Lusutinib cream, highlights the lack of specific treatments for vitiligo. Calcium channel modulators like tacrolimus ointment, corticosteroids such as dexamethasone cream, and vitamin D3 derivatives like calcipotriol ointment are commonly used, but none have received official indications for vitiligo treatment. Lusutinib cream, although approved for vitiligo, is currently limited to use in the Boao Medical Pilot Zone in Hainan. Therefore, there is a significant unmet clinical need in the vitiligo market.
• 2023-01-18
  

  Officially cut into the CAR-T track! Huadong Medicine obtained the commercialization rights of Zewoki Orencel injection, a CAR-T product of Keji Pharmaceutical

  Multiple myeloma is the second largest malignant blood disease in the world, and Huadong Medicine's core products in the field of blood diseases include cyclosporine soft capsules, mycophenolate mofetil capsules/dispersible tablets, tacrolimus capsules, decitabine for injection, sirolimus oral liquid, etc.
  pharmaceutical trend
• 2020-04-20
  

  New study identifies drugs that are safe to use in COVID-19 treatment

  The study also found that other types of drugs – such as TNF blockers and JAK inhibitors – are also safe to use in the treatment of COVID-19.The researchers analysed 89 existing studies on other coronaviruses such as MERS and SARS as well as the limited literature on COVID-19, to determine if certain pain medications, steroids and other drugs used by people already suffering from a disease should be avoided if they contract COVID-19.The study comes following speculation over the use of certain non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, to treat COVID-19, with some saying these drugs can actually make the condition worse.Earlier this month, French authorities criticised the use of certain anti-inflammatories – namely ibuprofen and cortisone – to treat the novel coronavirus disease.They warned that widely used over-the-counter anti-inflammatories may actually worsen the infection, adding that patients should opt for paracetamol if they experience a fever instead.The European Medicines Agency also responded to these reports, and advised that while there is no scientific evidence that drugs like ibuprofen worsen COVID-19, it is closely monitoring the situation.Certain individuals – such as cancer patients – may already be taking immunosuppressive drugs, which lowers the body’s immune system, or immunostimulant drugs which work to boost the immune system. Healthcare professionals need, therefore, to know which drugs should be stopped if a patient catches COVID-19.“This pandemic has led to challenging decision-making about the treatment of COVID-19 patients who were already critically unwell,” said Mieke Van Hemelrijck, a cancer epidemiologist at KCL and an author on the paper.“In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune suppressive medication,” she added.The study also found that low doses of prednisolone or tacrolimus therapy could be helpful in the treatment of COVID-19.“Current evidence suggests that low dose prednisolone (a steroid used to treat allergies) and tacrolimus therapy (an immunosuppressive drug given to patients who have had an organ transplant) may have beneficial impact on the course of coronavirus infections. However further investigation is needed,” said Sophia Papa, a medical oncologist and immunologist at KCL and co-author of the study.
  COVID-19 treatment